May 23, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 15, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical ...

The ASCO Post

May 12, 2025

CRISPR-Cas9-Edited TILs:  Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al evaluated whether autologous tumor infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 ...

The ASCO Post

May 01, 2025

DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths

A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halve...

The ASCO Post

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post

December 04, 2023

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers investigated whether the regular consumption of navy beans could help improve the gut microbiome of colorectal cancer survivors.

The ASCO Post